SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer 2015

• E. Aranda ^[1] ; J. Aparicio ^[9] ; V. Alonso ^[2] ; X. Garcia-Albeniz ^[10] ; P. Garcia-Alfonso ^[3] ; R. Salazar ^[4] ; M. Valladares ^[5] ; R. Vera ^[6] ; J. M. Vieitez ^[7] ; R. Garcia-Carbonero ^[8]
  1. [1] Instituto Maimónides de Investigación Biomédica de Córdoba

     Instituto Maimónides de Investigación Biomédica de Córdoba

     Cordoba, España

     
  2. [2] Hospital Miguel Servet

     Hospital Miguel Servet

     Zaragoza, España

     
  3. [3] Hospital General Universitario Gregorio Marañón

     Hospital General Universitario Gregorio Marañón

     Madrid, España

     
  4. [4] Institute Catalá Oncología

     Institute Catalá Oncología

     Barcelona, España

     
  5. [5] Complexo Hospitalario Universitario da Coruña

     Complexo Hospitalario Universitario da Coruña

     A Coruña, España

     
  6. [6] Gobierno de Navarra

     Gobierno de Navarra

     Pamplona, España

     
  7. [7] Hospital Universitario Central de Asturias

     Hospital Universitario Central de Asturias

     Oviedo, España

     
  8. [8] Hospital Universitario 12 de Octubre

     Hospital Universitario 12 de Octubre

     Madrid, España

     
  9. [9] Hospital Universitario y Politécnico La Fe
  10. [10] Harvard T.H. Chan School of Public Health

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 17, Nº. 12, 2015, págs. 972-981
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Colorectal cancer (CRC) is the second leading cause of cancer dead in Spain. About half the patients will eventually develop distant metastases. However, as treatment options are expanding, prognosis has steadily improved over the last decades. Management of advanced CRC should be discussed within an experienced multidisciplinary team to select the most appropriate systemic treatment (chemotherapy and targeted agents) and to integrate surgical or ablative procedures when indicated. Disease site and extent, resectability, tumor biology and gene mutations, clinical presentation, patient preferences, and comorbidities are key factors to design a customized treatment plan. The aim of these guidelines is to provide synthetic recommendations for managing advanced CRC patients.